# BioNTech SE: Form 20-F/A for the period ended Dec 31, 2021

- Company: [BioNTech SE](/companies/bntx.md) (CIK 1776985)
- Form: 20-F/A
- Filed: 2022-10-26
- Accepted by EDGAR: Oct 26, 2022, 17:20 ET
- Period: 2021-12-31
- Accession: 0000950170-22-020213
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1776985/000095017022020213/bntx-20211231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1776985/000095017022020213/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-01-01 to 2021-12-31 | EUR 18.98bn | ifrs-full:RevenueFromContractsWithCustomers |
| Cost of revenue | 12 months, 2021-01-01 to 2021-12-31 | EUR 2.91bn | ifrs-full:CostOfSales |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | EUR 15.28bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2021-01-01 to 2021-12-31 | EUR 4.75bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | EUR 10.29bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months, 2021-01-01 to 2021-12-31 | EUR 39.63 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2021-01-01 to 2021-12-31 | EUR 42.18 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | EUR 889.7m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-01-01 to 2021-12-31 | EUR 127.5m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2021-12-31 | EUR 1.69bn | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2021-12-31 | EUR 15.07bn | ifrs-full:CurrentAssets |
| Total assets | at 2021-12-31 | EUR 15.83bn | ifrs-full:Assets |
| Current liabilities | at 2021-12-31 | EUR 3.48bn | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2021-12-31 | EUR 3.94bn | ifrs-full:Liabilities |
| Shareholders' equity | at 2021-12-31 | EUR 11.89bn | ifrs-full:Equity |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1776985/000095017022020213/bntx-20211231.htm

Filed Oct 26, 2022.
Source: SEC EDGAR, the filing index for accession 0000950170-22-020213. Last ingested by Listed: Nov 3, 2026, 08:40 ET. No prices; not investment advice.